Another biomarker of great clinical significance is methylation of the MGMT (O6-methylguanine-DNA methyltransferase) gene promoter, which leads to epigenetic silencing of this gene and reduces the ability of cancer cells to repair DNA damage caused by alkylating cytostatics such as temozolomide [50]. Here, MGMT is linked to cancer.